drugset / Trial / NCT04484350

Blood Pressure Management in Stroke Following Endovascular Treatment

NCT04484350

Phase 2 Completed 30 enrolled Hamilton Health Sciences Corporation
RandomizedParallel-groupSingle-blindTreatment

Summary

The aim of DETECT is to prove the feasibility of a multicenter phase III trial testing the hypothesis that intensive blood pressure control immediately after successful endovascular stroke thrombectomy can improve patient outcomes. Patients with stroke who have ongoing high blood pressure after successful clot retrieval will be included. Participants will be randomly placed (like flipping a coin) in one of two groups. There will be a 50% chance of each patient being placed to either group. The first group will be allowed to have a higher blood pressure range that is consistent with current recommendations. The second group will be given medications to bring their blood pressure down into a normal range. These blood pressure targets will be maintained for 48 hours. We will collect patient brain images and levels of stroke disability up to 90 days after their clot retrieval.

Timeline

Start
2020-10-23
Primary completion
2023-02-04
Completion
2023-05-04

Drugs

EvaluationDrugModalityDoseRoute
Background Enalapril Other / unclassified 1.25 mg Intravenous
Background Enalapril Other / unclassified 2.5 mg Intravenous
Background Hydralazine Small molecule 10 mg Intravenous
Background Hydralazine Small molecule 20 mg Intravenous
Background Labetalol Small molecule 10 mg Intravenous
Background Labetalol Small molecule 20 mg Intravenous